Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Patrick J. McEnany 

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

Operations and Strategy

Corporate Strategy and Business Development

Finance and Accounting

Regulatory and Compliance

��

Teams at Catalyst Pharmaceuticals

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

Operations and Strategy

Corporate Strategy and Business Development

Finance and Accounting

Regulatory and Compliance

��������

Teams at Catalyst Pharmaceuticals

Medical Affairs and Patient Advocacy

Board and Governance

Leadership Team

Operations and Strategy

Corporate Strategy and Business Development

Finance and Accounting

Regulatory and Compliance

��